JAMA : the journal of the American Medical Association
-
This study uses Medicare claims data to compare spending for hip and joint replacements among hospitals with voluntary vs mandatory participation vs nonparticipation in the Medicare Bundled Payments for Care Improvement program between 2011 and 2017.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
Intravenous eptinezumab, an anti-calcitonin gene-related peptide antibody, is approved for migraine prevention in adults. It has established onset of preventive efficacy on day 1 after infusion. ⋯ Among patients eligible for preventive migraine therapy experiencing a moderate to severe migraine attack, treatment with intravenous eptinezumab vs placebo shortened time to headache and symptom resolution. Feasibility of administering eptinezumab treatment during a migraine attack and comparison with alternative treatments remain to be established.